First human tests of new HIV vaccine show promise
NCT ID NCT05854381
Summary
This study tested the safety and immune response of an experimental HIV vaccine called VIR-1388. The trial involved 93 healthy adults without HIV who received either the vaccine or a placebo. Researchers monitored participants for side effects and measured whether the vaccine triggered immune responses that might protect against HIV infection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV I INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS
Birmingham, Alabama, 35222, United States
-
Beth Israel Deconess Medical Center VCRS
Boston, Massachusetts, 32077, United States
-
Chatsworth Clinical Research Site
Overport, KwaZulu-Natal, 4092, South Africa
-
Isipingo Clinical Research Site
Isipingo, KwaZulu-Natal, 4110, South Africa
-
Penn Prevention CRS
Philadelphia, Pennsylvania, 19104, United States
-
Perinatal HIV Research Unit
Soweto, Gauteng, 1862, South Africa
-
Seattle Vaccine and Prevention CRS
Seattle, Washington, 98104, United States
-
Setshaba Research Centre CRS
Soshanguve, Gauteng, 0152, South Africa
-
The Hope Clinic of the Emory Vaccine Center CRS
Decatur, Georgia, 30030, United States
-
University of Pittsburgh CRS
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.